| Date Filed | Type | Description |
| 05/23/2023 |
4
| Pruzanski Mark (Director) has filed a Form 4 on Equillium, Inc.|
Txns:
| Granted 20,000 options to buy
@ $0.65, valued at
$13k
|
|
| 05/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2021 |
4
| Pruzanski Mark (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 6,138 shares
@ $16.86, valued at
$103.5k
Paid exercise price by delivering 3,817 shares
@ $16.86, valued at
$64.4k
|
|
| 10/04/2021 |
4
| Pruzanski Mark (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 6,136 shares
@ $14.85, valued at
$91.1k
Paid exercise price by delivering 3,816 shares
@ $14.85, valued at
$56.7k
|
|
| 09/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/02/2021 |
4
| Pruzanski Mark (Director) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 6,138 shares
@ $17.28, valued at
$106.1k
Paid exercise price by delivering 3,817 shares
@ $17.28, valued at
$66k
|
|
| 07/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/21/2020 |
4
| Pruzanski Mark (Director) has filed a Form 4 on Equillium, Inc.|
Txns:
| Granted 24,000 options to buy
@ $2.8, valued at
$67.2k
|
|
| 04/03/2020 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 568 shares
@ $58.4, valued at
$33.2k
|
|
| 01/27/2020 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 10,800 shares
@ $0
Granted 17,700 options to buy
@ $99.66, valued at
$1.8M
|
|
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/30/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/27/2019 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Sold 14,563 shares
@ $100, valued at
$1.5M
Sold 35,437 shares
@ $100, valued at
$3.5M
Exercised 39 options to buy
@ $8.6667, valued at
$338
Exercised 14,524 options to buy
@ $8.6667, valued at
$125.9k
Exercised 19,880 options to buy
@ $8.6667, valued at
$172.3k
Exercised 15,557 options to buy
@ $21.5, valued at
$334.5k
|
|
| 10/03/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2019 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,548 shares
@ $79.17, valued at
$122.6k
|
|
| 06/13/2019 |
4
| Pruzanski Mark (Director) has filed a Form 4 on Equillium, Inc.|
Txns:
| Granted 12,000 options to buy
@ $6.01, valued at
$72.1k
|
|
| 04/03/2019 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,547 shares
@ $111.5, valued at
$172.5k
|
|
| 01/18/2019 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Granted 8,500 shares
@ $0
Granted 13,700 options to buy
@ $110.8, valued at
$1.5M
|
|
| 01/03/2019 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,537 shares
@ $100.79, valued at
$154.9k
|
|
| 11/16/2018 |
4
| Pruzanski Mark (President & CEO) has filed a Form 4 on INTERCEPT PHARMACEUTICALS, INC.|
Txns:
| Sold 18,873 shares
@ $100.3813, valued at
$1.9M
Sold 3,521 shares
@ $101.1327, valued at
$356.1k
Sold 9,830 shares
@ $100.38, valued at
$986.7k
Sold 7,949 shares
@ $101.4828, valued at
$806.7k
Sold 7,839 shares
@ $102.6118, valued at
$804.4k
Sold 1,988 shares
@ $103.286, valued at
$205.3k
Exercised 22,394 options to buy
@ $8.6667, valued at
$194.1k
Exercised 27,606 options to buy
@ $8.6667, valued at
$239.3k
|
|
| 10/11/2018 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/03/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/09/2018 |
4
| Pruzanski Mark (CEO & President) has filed a Form 4 on INTERCEPT PHARMACEUTICALS INC|
Txns:
| Bought 7,812 shares
@ $64, valued at
$500k
|
|
| 02/22/2018 |
4
| Pruzanski Mark (CEO & President) has filed a Form 4 on INTERCEPT PHARMACEUTICALS INC|
Txns:
| Granted 45,500 options to buy
@ $58.74, valued at
$2.7M
|
|
|